BioNTech (BNTX) financials
BioNTech revenue and earnings by year
BioNTech's revenue was $3.38 billion in the fiscal year to December 31, 2025, up 17.8% from the year before. Net income was -$1.34 billion, -39.6% of revenue. Since the fiscal year to December 31, 2017, revenue has grown 61.2% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 9 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.4 | 2.9 | 4.2 | 18.4 | 21.6 | 0.6 | 0.1 | 0.1 | 0.1 |
| Revenue growth | 17.8% | -32.5% | -77.0% | -14.6% | 3566.4% | 382.0% | -16.8% | 98.3% | — |
| Gross profit | 2.6 | 2.3 | 3.6 | 15.2 | 18.3 | 0.5 | 0.1 | 0.1 | 0.1 |
| Gross margin | 77.6% | 80.3% | 84.3% | 82.7% | 84.7% | 87.7% | 84.0% | 89.3% | 84.9% |
| Operating income | -1.7 | -1.4 | 0.8 | 13.4 | 17.4 | -0.1 | -0.2 | -0.1 | -0.1 |
| Operating margin | -49.0% | -47.8% | 18.1% | 73.0% | 80.5% | -17.1% | -167.1% | -42.2% | -99.5% |
| Net income | -1.3 | -0.7 | 1.0 | 10.0 | 11.7 | 0.0 | -0.2 | -0.1 | -0.1 |
| Net margin | -39.6% | -24.2% | 24.4% | 54.5% | 54.2% | 3.2% | -164.9% | -37.6% | -139.1% |
| Diluted EPS | -$5.37 | -$3.03 | $4.16 | $40.13 | $46.35 | $0.17 | -$0.95 | — | — |
| Free cash flow | 0.3 | -0.1 | 5.7 | 14.1 | 0.8 | -0.1 | -0.3 | -0.1 | -0.1 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open BNTX in Markets.
See also: BNTX valuation and P/E history · BNTX returns
No forecast, no recommendation. This page describes BioNTech from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.